Century Therapeutics

Philadelphia, United States Founded: 2018 • Age: 8 yrs Listed
Developer of adult stem cells to develop therapies for cancer

About Century Therapeutics

Century Therapeutics is a publicly listed company based in Philadelphia (United States) founded in 2018. Developer of adult stem cells to develop therapies for cancer. Century Therapeutics has raised $410 million across 4 funding rounds from investors including Fidelity Investments, Marshall Wace and FUJIFILM Cellular Dynamics. The company has 150 employees. Century Therapeutics has completed 3 acquisitions, including Clade TX, Empirica Therapeutics and empirica. Century Therapeutics offers products and services including iPSC-derived NK Cell Therapies and iPSC-derived T Cell Therapies. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is Century Therapeutics, Inc.

Company details

Century Therapeutics was founded in 2018 and is headquartered in Philadelphia, United States. Operations focus on the biotechnology sector, where adult stem cells are harnessed to create therapies targeting cancer. Novel allogeneic living drugs for oncology are being developed to address shortcomings in first-generation cell therapies. The companys efforts center on advancing these cellular treatments through research and development processes.

  • Headquarters Philadelphia, United States
  • Employees 150
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Website centurytx.com
  • Social LinkedIn X
  • Legal Name Century Therapeutics, Inc.
Operational Areas
Key Metrics
  • Annual Revenue
    $109.16 M (USD)
    1556.76
    as on Dec 31, 2025
  • Net Profit
    -$9.58 M (USD)
    92.43
    as on Dec 31, 2025
  • EBITDA
    -$1.94 M (USD)
    98.4
    as on Dec 31, 2025
  • Total Equity Funding
    $410M (USD)

    in 4 rounds

  • Latest Funding Round
    $135M (USD), Post-IPO

    Jan 2026

  • Investors
  • Employee Count
    150
  • Investments & Acquisitions
    Clade TX

    & 2 more

Products & Services of Century Therapeutics

Century Therapeutics offers a comprehensive portfolio of products and services, including iPSC-derived NK Cell Therapies and iPSC-derived T Cell Therapies.

iPSC-derived NK Cell Therapies
Cell Therapy

Engineered cells for cancer treatment through immune response.

iPSC-derived T Cell Therapies
Cell Therapy

Therapies targeting autoimmune diseases via cellular engineering.

Funding Insights of Century Therapeutics

Century Therapeutics has successfully raised a total of $410M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $135 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $410M
  • Total Rounds 4
  • Last Round Post-IPO β€” $135M
  • First Round $250M

    (Jul 2019)

  • Investors Count 24

All 4 funding rounds of Century Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jan 2026$135MPost-IPO–TCG Crossover
Apr 2024$60MPost-IPO––
Mar 2021$160MSeries C–Casdin Capital
Jul 2019$250MSeries C–Leaps by Bayer
Valuation history

24 investors in total: 24 institutional.

Investors in Century Therapeutics

Century Therapeutics has secured backing from 24 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, Marshall Wace and FUJIFILM Cellular Dynamics.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Investments are focused on pharmaceutical, biotechnology, and medical sectors.
baincapitallifesciences.comBoston, United States
Investments in healthcare startups are managed by Octagon Capital Advisors.
octagoninvestments.comNew York, United States
Investment firm focused on global life sciences and healthcare.
superstringcap.comNew York, United States
Investing in Life Sciences sectors like Healthcare and Biotechnology.
casdincapital.com
Biotech startups are funded by this venture capital firm.
boxercap.comSan Diego, United States
VC & PE firm focused on healthcare sector
venrockcp.comPalo Alto, United States
Private equity fund focused on the biotechnology sector
logoscapital.comSan Francisco, United States
Long-short equity strategies are managed through specialized hedge funds.
1997mwam.comLondon, United Kingdom
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
1989orbimed.comNew York, United States
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
versantventures.com
Premium access

Investor details for Century Therapeutics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Century Therapeutics

33 people are tracked at Century Therapeutics (11 in leadership, 11 in board & advisors, 11 in team); the tracked headcount is 150.

NameRoleGroup
Danielle Menniti
Executive Director, Head Of QualityLeadership
Venkatesh Hariharan
DirectorLeadership
Johanna O'Bannon
Associate Director, QC MicrobiologyLeadership
Greg Russotti
Chief Technology And Manufacturing OfficerLeadership
Michael Naso
VP, Cell EngineeringLeadership
Bruno Marques
VP, Process & Product DevelopmentLeadership
Buddha Gurung
Director, Cell EngineeringLeadership
Bruce Mittleman
Head Of Information TechnologyLeadership
Keith Wilson
Director, Manufacturing Science And TechnologyLeadership
Lindsay Mercado
Associate Director, Quality EsystemsLeadership
Nayyereh Rajaei
Director, Drug Product Development And DeliveryLeadership
Joe Jimenez
ChairmanBoard & advisors
Eli Casdin
DirectorBoard & advisors
Hiromitsu Nakauchi
Scientific AdvisorBoard & advisors
Barbara Kee
Scientific AdvisorBoard & advisors
Kimberly Blackwell
DirectorBoard & advisors
Alessandro Riva
DirectorBoard & advisors
Ellen Rothenberg
Scientific AdvisorBoard & advisors
Cynthia Butitta
Independent DirectorBoard & advisors
Carlo Rizzuto
DirectorBoard & advisors

13 more people are available in the full profile.

Premium access

Complete people profiles for Century Therapeutics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Century Therapeutics

Century Therapeutics is a publicly listed company on the NASDAQ with ticker symbol IPSC in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date18 Jun 2021
  • Listed onNASDAQ: IPSC
  • Listed entityCentury Therapeutics, Inc.
  • Exchange sectorHealth technology
  • ISINUS15673T1007
  • Share price$1.38 (-4.17% on the day) · 2026-10-13
  • Market capitalisation$249.9M
  • EPS (diluted, trailing year)$-0.90
  • Volume (last session)544,254

Financials of Century Therapeutics

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025$109.2M-$9.6M-$1.9M
2024$6.6M-$126.6M-$121.0M
2023$2.2M-$136.7M-$112.1M
2022$5.2M-$130.9M-$113.8M
2021-$95.8M-$90.3M
Premium access

Detailed financial statements for Century Therapeutics

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Century Therapeutics

Century Therapeutics has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Clade TX, Empirica Therapeutics and empirica.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Stem cell-derived therapies for cancer are developed using pluripotent cells.
cladetx.comCambridge, United States2020Apr 2024β€’β€’β€’β€’
Research and consulting services are provided by empirica.
empirica.comBonn, Germany1988Jul 2020β€’β€’β€’β€’
T-cell therapeutics are developed for brain cancer treatment.
empiricatx.comHamilton, Canada2018Jun 2020β€’β€’β€’β€’
Premium access

Complete acquisition details for Century Therapeutics

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Century Therapeutics

7 dated milestones of Century Therapeutics across 8 years, from founding to its latest funding, stage changes and deals.

  1. Founded Century Therapeutics is founded.
  2. Funding First funding round of $250.0M.
  3. Acquisition Acquires Empirica Therapeutics.
  4. Acquisition Acquires empirica.
  5. IPO Lists on the stock exchange (IPO).
  6. Acquisition Acquires Clade TX.
  7. Funding Latest funding round, Post-IPO, of $135.0M.

Web traffic of Century Therapeutics

The website of Century Therapeutics (centurytx.com) receives about 9.7K visits a month and ranks #3,364,929 among all websites worldwide, #4,406 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    9.7K

    ▲ 78.1% vs previous month

  • Unique visitors
    2.2K

    per month

  • Global rank
    #3,364,929

    among all websites

  • Category rank
    #4,406

    Health · Biotechnology and Pharmaceuticals

Top companies in Oncology

3 companies that operate in the same segment as Century Therapeutics (Oncology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Century Therapeutics

Premium access

Complete news archive for Century Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Century Therapeutics

Century Therapeutics was founded in 2018 and raised its 1st funding round 1 year after it was founded.

Century Therapeutics is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.

Century Therapeutics is a funded company, having raised a total of $410M across 4 funding rounds to date. The company's 1st funding round was a Series C of $250M, raised on Jul 2019.

Century Therapeutics has 150 employees.

Annual revenue of Century Therapeutics is $109.16M as on Dec 31, 2025.

Century Therapeutics was founded in 2018 and is headquartered in Philadelphia, United States. Operations focus on the biotechnology sector, where adult stem cells are harnessed to create therapies targeting cancer. Novel allogeneic living drugs for oncology are being developed to address shortcomings in first-generation cell therapies. The companys efforts center on advancing these cellular treatments through research and development processes.

Century Therapeutics offers iPSC-derived NK Cell Therapies and iPSC-derived T Cell Therapies.

Yes, Century Therapeutics is publicly traded on NASDAQ under the ticker symbol IPSC.

Century Therapeutics has made 3 acquisitions, including Clade TX, Empirica Therapeutics, and empirica.

Century Therapeutics has 24 investors. Key investors include Fidelity Investments, Marshall Wace, FUJIFILM Cellular Dynamics, Orbimed, and RA Capital.

Century Therapeutics operates through Century Therapeutics, Inc..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available